Top Story

Patent filed for injectable HBV, liver cancer drug in China

September 18, 2014

Biostar Pharmaceuticals has filed an invention and creation patent application in China for oleanolic acid injection for the treatment of hepatitis B virus infection and liver cancer, according to a news release.

The drug, currently under pharmacological research, passed the preliminary examination of the People’s Republic of China State Intellectual Property Bureau, the release said.

In the Journals

Half of patients with HIV not screened regularly for HCV

September 17, 2014
Researchers from Boston Medical Center have found that although most patients with HIV were screened for hepatitis C virus infection when enrolling into care, only half…

Sovaldi use decreased; analysts anticipate rise with release of newer therapies for HCV

September 17, 2014
The rate at which patients have used sofosbuvir to treat hepatitis C virus infection has declined in recent months, according to an analysis performed by the CVS Health…
figure In the Journals

HAV in the Middle East and North Africa (MENA) region declined in younger populations

September 17, 2014
Seroprevalence trends in hepatitis A virus infection indicated a decline among younger populations in the Middle East and North Africa region, while areas with less…
figure

Top 10 Questions on HCV Infection

Gain expert insight on HCV infection, including symptoms, age-based screening guidelines and treatment…
More »
Meeting News Coverage Video
figure

Tenofovir/entecavir recommended for HBV patients with malignancy

May 16, 2014
CHICAGO — Spilios Manolakopoulos, MD, of the internal medicine and hepatology departments at…
More »
figure

Top 5 Questions on New Treatments for Chronic Hepatitis C Infection

Learn more about new medications on the horizon for treating HCV infection.
More »

Filter By:

Patent filed for injectable HBV, liver cancer drug in China

September 18, 2014
Biostar Pharmaceuticals has filed an invention and creation patent application in China for oleanolic acid injection for the treatment of hepatitis B…
In the Journals

Half of patients with HIV not screened regularly for HCV

September 17, 2014
Researchers from Boston Medical Center have found that although most patients with HIV were screened for hepatitis C virus infection when enrolling…

Sovaldi use decreased; analysts anticipate rise with release of newer therapies for HCV

September 17, 2014
The rate at which patients have used sofosbuvir to treat hepatitis C virus infection has declined in recent months, according to an analysis…
figure In the Journals

HAV in the Middle East and North Africa (MENA) region declined in younger populations

September 17, 2014
Seroprevalence trends in hepatitis A virus infection indicated a decline among younger populations in the Middle East and North Africa region, while…

Gilead OKs generic licensing deals in India for Sovaldi

September 15, 2014
Gilead Sciences has signed licensing agreements that will allow seven Indian pharmaceutical manufacturers to produce generic versions of sofosbuvir…
Meeting News Coverage

HBV, HIV seroprevalence high among pregnant women at Cameroon clinic

September 9, 2014
WASHINGTON, D.C. — Pregnant women in Cameroon had a high seroprevalence for hepatitis B virus infection and HIV, but not hepatitis C virus…
figure In the Journals

HEV seroprevalence declined by 70% in US since 1994

September 9, 2014
The seroprevalence of hepatitis E virus infection in the US has decreased more than threefold since the 1990s, according to a study that examined…
figure In the Journals

Treat-all strategy more cost effective than noninvasive tests for HCV patients

September 4, 2014
The most cost-effective strategy to determine treatment for patients with hepatitis C virus infection in the United Kingdom was to treat all patients…
figure In the Journals

Hispanic veterans with HCV at higher risk for cirrhosis, HCC

September 1, 2014
Hispanic veterans with hepatitis C virus infection had a higher risk for developing cirrhosis or hepatocellular carcinoma compared with…
In the Journals

HEV antibody prevalence decreased since 1988

August 27, 2014
New data from a CDC study indicate that the prevalence of hepatitis E virus antibodies has decreased significantly from 1988-1994 to…
More Headlines »